

“Molecular Clinical Oncology”

Organizing Committee:

Paolo M.Comoglio, Alberto Bardelli, Livio Trusolino

Scientific Secretariat:

Silvia Marsoni

Institute for Cancer Research @ Candiolo



Venue

The conference location will be Centro Congressi Torino Incontra, in the heart of the historical city center. Torino is a renowned town, a European cultural center, nestled in an area of natural beauty with the mountains close to the city. Being the first capital of the unified Kingdom of Italy in 1861, Torino will celebrate the 150th anniversary of Italy as a nation with a series of cultural events that will culminate in May, when the conference will be held.

A Burgeoning Medical Science



Paolo M. Comoglio M.D.

“Molecular Clinical Oncology” is a novel discipline translating biology into medicine. Targeting single genetic lesions can interfere with tumor growth notwithstanding the multitude of genetic alterations harbored by cancers. This has given an unprecedented clinical value to the concept that cancer is a disease of genes, a dogma in molecular oncology that is now practically exploited by clinicians to set up novel classifications of tumors based on the presence of defined genetic lesions. Thanks to these advances, the idea of giving a patient a drug tailored to the genetic makeup of the tumor is becoming commonplace.

Despite encouraging success, much remains to be done in terms of patient genotyping and stratification, identification of prognostic biomarkers, and investigation of mechanisms of drug resistance. This conference will address these issues from bench to bedside in five plenary sessions, spanning genetics, molecular biology, cancer stem cell biology, molecular diagnosis and prognosis. The ultimate goal of personalized cancer therapies will be discussed and mechanisms of resistance to target therapies will be addressed.

The invited speakers are world renowned experts in their respective areas. Short talk and poster presentations will be selected from participants.

Sponsored by Gruppo di Cooperazione in Cancerologia

www.cancercoop.org

Invited Speakers

Alan Ashworth, London - United Kingdom
Alberto Bardelli, Candiolo - Italy
Federico Cappuzzo, Livorno - Italy
Fortunato Ciardiello, Napoli - Italy
Jeffrey A Engelman, Charlestown - USA
Karen Gelmon, Vancouver - Canada
Pasi A. Janne, Boston - USA
Roberto Labianca, Bergamo - Italy
John Laterra, Baltimore - USA
Pierre Laurent-Puig, Paris - France
Richard Marais, London - United Kingdom
Pier Paolo Pandolfi, Boston - USA
William Pao, Nashville - USA
PierGiuseppe Pelicci, Milano - Italy
Neal Rosen, New York - USA
William Sellers, Cambridge - USA
Salvatore Siena, Milano - Italy
David B Solit, New York - USA
Jean-Charles Soria, Villejuif - France
Joseph Tabernero, Barcelona - Spain
Sabine Tejpar, Leuven - Belgium
Ian Tomlinson, Oxford - United Kingdom
Livio Trusolino, Candiolo - Italy

Contacts:

Antonella Cignetto

Phone: +39-011-9933.601—Fax: +39-011-9621.525

E-mail: mol-clin-onc@cancercoop.org

IRCC—Institute for Cancer Research @ Candiolo

Strada Provinciale 142 Km 3,95 - 10060 Candiolo (TO) - Italy

2011 IRCC International Conference - May 26th-28th, 2011 Torino - Italy

Thursday May 26th, 2011 (Aula Magna Rettorato)

- 14.00 Registration
- 15.45 Welcome address
Paolo Comoglio (Italy)
“Molecular Clinical Oncology: a Novel Discipline”

Cancer Stem Cells

- 16.00 PierGiuseppe Pelicci (Italy)
“Breast Cancer Stem Cells”
- 16.30 John Laterra (USA)
“Regulation of Glioblastoma Stem Cells: Reprogramming Factors and Receptor Tyrosine Kinases”
- 17.00 Selected Short talks

Keynote Lecture

- 17.30 Jeffrey A.Engelman (USA)
“Cancer Targeted Therapy”

Friday May 27th, 2011 (Centro Congressi Torino Incontra)

Cancer Genes

- 08.00 Pier Paolo Pandolfi (USA)
“Deconstructing the Molecular Genetics of Cancer”
- 08.30 David B Solit (USA)
“Genetic Determinants of RAS/BRAF Dependence”
- 09.00 Richard Marais (UK)
“BRAF and RAS Signalling in Melanoma: Basic Biology and Therapeutic intervention”
- 10.00 Jean-Charles Soria (France)
“Targeting DNA Repair Dysfunctionality in Lung Cancer”
- 10.30 Livio Trusolino (Italy)
“MET in Human Cancer: Targeting Oncogene Addiction and Expedience”
- 11.00 Selected Short Talks
- 11.30 Poster Session

Molecular Diagnosis and Prognosis

- 15.00 Ian Tomlinson (UK)
“Predisposition to Colorectal and Other Cancers”
- 15.30 Sabine Tejpar (Belgium)
“Molecular Subgroups in Colorectal Cancer: Prognostic and Predictive Implications”
- 16.00 Roberto Labianca (Italy)
“Prognostic and Predictive Biomarkers for Colorectal Cancer in the Adjuvant Setting”
- 17.00 Pierre Laurent-Puig (France)
“Theranostic Biomarkers in Metastatic Colorectal Cancer”
- 17.30 Joseph Taberero (Spain)
“Introduction of Biomarkers in Early Clinical Development”
- 18.00 Selected Short Talks

Saturday May 28th, 2011 (Centro Congressi Torino Incontra)

Personalized Cancer Therapies: Concepts and Targets

- 08.30 Alan Ashworth (UK)
“Synthetic Lethal Approaches to Cancer Therapy”
- 09.00 Neal Rosen (USA)
“Unconventional Oncogenic Signalling”
- 09.30 William Sellers (USA)
“Kinase Inhibitors in Cancer Therapy”
- 10.00 Federico Cappuzzo (Italy)
“Anti-EGFR Strategies against Metastatic NSCLC”
- 11.00 Karen Gelmon (Canada)
“Hypothesis Driven Trials in Breast Cancer”
- 11.30 Alberto Bardelli (Italy)
“Cancer Mutations and Targeted Therapies in Cells, Mice and Patients”
- 12.00 Selected Short Talks
- 14.00 Poster Session

Personalized Cancer Therapies: Overcoming Resistances

- 16.00 William Pao (USA)
“Novel Strategies to Delay/Treat Acquired Resistance to EGFR TKIs in EGFR Mutant Lung Cancer”
- 16.30 Pasi A. Janne (USA)
“Therapeutic Strategies for EGFR and ALK Kinase Inhibitor Resistant Cancers”
- 17.00 Fortunato Ciardiello (Italy)
“Acquired Resistance to EGFR-targeted Therapies”
- 17.30 Salvatore Siena (Italy)
“Molecular Driven Selection Improves Survival of Metastatic Colorectal Cancer Patients”
- 18.00 Selected Short Talks

Under the Auspices of

- AIRC Special Program in Molecular Clinical Oncology
- Fondazione Piemontese per la Ricerca sul Cancro - ONLUS
- Università degli Studi di Torino
- ESMO - European Society for Medical Oncology
- Regione Piemonte
- Farmaindustria
- Fondo Edo Tempia